Ultragenyx wins two FDA approvals and cuts 20% of its workforce
FROM THE WIRE · FINANCE.YAHOO.COM
Ultragenyx Pharmaceutical (RARE) is in focus after receiving FDA approvals for its first two commercial gene therapies, GENGLYCOS and FAYUVI, while simultaneously cutting 20% of its workforce and discontinuing two development programs. The latest moves have arrived after a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralNew approvals and cost cuts matter for the stock, but the 90-day and 1-year declines weigh on sentiment.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01FDA approved its first two commercial gene therapies, GENGLYCOS and FAYUVI.
- 02The company is cutting 20% of its workforce and discontinuing two development programs.
- 03The share price return is +9.26% over 1 month, but -33.29% over 90 days.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets